Quarterly report [Sections 13 or 15(d)]

Schedule of Accounts Payable to Related Party (Details)

v3.25.3
Schedule of Accounts Payable to Related Party (Details) - Cytovance Biologics Inc [Member] - USD ($)
1 Months Ended 9 Months Ended
Mar. 31, 2025
Sep. 30, 2025
Sep. 30, 2024
Defined Benefit Plan Disclosure [Line Items]      
Beginning balance   $ 1,183,000 [1] $ 3,515,000
Invoices, net   686,000 1,365,000
Payments in cash   (962,000) (3,432,000)
Payments in common stock, at fair value   (810,000)
Payments in pre-funded warrants, at fair value $ (847,000) (847,000)
Ending balance   $ 60,000 [1] $ 638,000
[1] Accounts Payable to Cytovance, a related party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock. See Note 7 – Commitments and Contingencies, Significant Agreements.